Shareholders of Angiotech Pharmaceuticals Inc. (TSX:ANP) are ruing the day the company hitched its wagon to Boston Scientific Corp. (NYSE:BSX) and its Taxus drug-eluting stent, as the Canadian pharma and medical device maker enters bankruptcy protection north of the border.
News Well
NDI Medical launches venture fund for medical device startups
Ohio has a new healthcare-focused venture fund that’s being led by a familiar Cleveland name.
Neurotechnology incubator NDI Medical LLC, best known for its $42 million sale of a urinary incontinence-treating product to Medtronic in 2008, has started NDI Healthcare Fund with the help of a $2 million grant from Ohio’s Third Frontier technology acceleration program.
Artificial pancreas could make pregnancy safer for diabetic women
Doc wins $482 million from Johnson & Johnson in patent case
Dr. Bruce Saffran added another corporate scalp to his trophy shelf, winning a $482 million verdict in a patent infringement suit against Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. over stent technology.
BioTime buys out Cell Targeting
Stem cell technology developer Cell Targeting Inc. sold its assets to BioTime Inc. (AMEX:BTX) in a deal worth about $2.3 million.
BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s common stock, which was trading around $7.75 at mid-day.
Funding roundup: Fresenius raises $1 billion through debt offering
Here’s a roundup of the latest dealflow and investment news:
Uroplasty CEO: 14 percent jump in sales reveals potential
Uroplasty Inc.’s (NSDQ:UPI) performance finally “began to reflect the potential of the company” in the third quarter, CEO David Kaysen said during the company’s earnings call.
The Minnetonka, Minn.-based device company ramped up its sales force, won over five new regional Medicare carriers, and boosted global revenue by 14 percent to $3.5 million during the quarter, which ended Dec. 31.
Distribution deals roundup: Varian lands $450 million Toshiba contract
Here’s a roundup of companies announcing new distribution deals.
Arteriocyte lands FDA nod for critical limb ischemia clinical trial
Stem cell developer Arteriocyte has received approval from the Food & Drug Administration to begin a Phase 1 clinical trial for the treatment of critical limb ischemia.
The trial will investigate the use of Arteriocyte’s Magellan technology to improve blood flow in patients suffering from critical limb ischemia (CLI), a severe obstruction of the arteries that reduces blood flow to hands, feet or legs, according to the Cleveland-based company. Serious cases can lead to amputation.
Studies roundup: Boston Scientific wraps up clinical milestones on Promus and Synergy stents
Here’s a roundup of the latest dealflow and investment news:
South Carolina company developing video-based EMR
Electronic medical records are still making their way into physicians’ offices, but a South Carolina startup thinks it’s already spotted a missing piece of the technology — video.
CareCam Innovations LLC received a $200,000 investment from SCRA, a Columbia, S.C.-based applied research and commercialization company.
The funding came from SCRA’s SC Launch program, which supports startups.